IBSP Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P21815 |
---|---|
Clone Names | 100507001 |
Gene ID | 3381 |
---|---|
Other Names | Bone sialoprotein 2, Bone sialoprotein II, BSP II, Cell-binding sialoprotein, Integrin-binding sialoprotein, IBSP, BNSP |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP14114a was selected from the N-term region of IBSP. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | IBSP |
---|---|
Synonyms | BNSP |
Function | Binds tightly to hydroxyapatite (PubMed:11459848). Appears to form an integral part of the mineralized matrix (PubMed:1818768). Probably important to cell-matrix interaction (PubMed:1818768). Promotes adhesion and migration of various cells via the alpha-V/beta-3 integrin receptor (ITGAV:ITGB3) (PubMed:10640428, PubMed:11459848, PubMed:24103036). |
Cellular Location | Secreted. |
Tissue Location | Expressed in bone (at protein level) (PubMed:11459848). Expressed in trophoblast cells of placenta (at protein level) (PubMed:1818768). Expressed in brain (PubMed:36261010) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a major structuralprotein of the bone matrix. It constitutes approximately 12% of thenoncollagenous proteins in human bone and is synthesized byskeletal-associated cell types, including hypertrophicchondrocytes, osteoblasts, osteocytes, and osteoclasts. The onlyextraskeletal site of its synthesis is the trophoblast. Thisprotein binds to calcium and hydroxyapatite via its acidic aminoacid clusters, and mediates cell attachment through an RGD sequencethat recognizes the vitronectin receptor.
References
Giroux, S., et al. Bone 47(5):975-981(2010)Koller, D.L., et al. J. Clin. Endocrinol. Metab. 95(4):1802-1809(2010)Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009)Gordon, J.A., et al. J. Cell. Biochem. 107(6):1118-1128(2009)Hwang, Q., et al. BMC Cancer 9, 121 (2009) :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.